[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-350469-105":59,"doc-detail-350469-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","chimeric-antigen-receptor-t-cell-therapy-for-the-treatment-of-melanoma-a-systematic-review-of-phase-one-clinical-trials-preliminaries-and-safetyefficacy-summary","Chimeric Antigen Receptor T-Cell Therapy for the Treatment of Melanoma - A Systematic Review of Phase One Clinical Trials - Preliminaries and Safety/Efficacy Summary","","Chimeric antigen receptor (CAR) T-cell therapy is evaluated as an emerging treatment option for melanoma, where refractory disease has limited therapeutic choices. A systematic review of phase one clinical trials was conducted using Cochrane and PRISMA guidance, searching literature available before November 18, 2025. Among 2726 screened articles, 5 studies covering 15 melanoma patients were analyzed, reporting autologous CAR-T products targeting GD2, PD-1, and cMET across varying cell doses. Across pooled data, responses ranged from partial to complete, treatment-related effects were mainly grade 1–2, and no serious adverse effects or neurotoxicity were reported; expansion peaked between day 7 and 28 with limited persistence.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/chimeric-antigen-receptor-t-cell-therapy-for-the-treatment-of-melanoma-a-systematic-review-of-phase-one-clinical-trials-preliminaries-and-safetyefficacy-summary/350469/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/chimeric-antigen-receptor-t-cell-therapy-for-the-treatment-of-melanoma-a-systematic-review-of-phase-one-clinical-trials-preliminaries-and-safetyefficacy-summary/350469.png","ImageObject",300,407,{"name":92,"@type":93},"Aran","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-12","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"How were phase one trials selected in the systematic review?","Question",{"text":112,"@type":113},"The review followed Cochrane guidance and PRISMA recommendations, searching databases for articles published before November 18, 2025 that reported CAR T-cell therapy in melanoma patients.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What did the review find about clinical responses in melanoma patients?",{"text":117,"@type":113},"Across five included studies (15 patients), pooled responses varied, with some patients achieving either partial or complete clinical responses.",{"name":119,"@type":110,"acceptedAnswer":120},"What safety outcomes were reported for CAR T-cell therapy in these phase one trials?",{"text":121,"@type":113},"Treatment-related effects were predominantly grade 1–2, and no serious adverse effects, including neurotoxicity-related events, were reported; limited toxicity and no treatment-related mortality events were described.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},350469,1790560935,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},137455076865,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","Chimeric Antigen Receptor T-Cell Therapy for the Treatment of Melanoma: A Systematic Review of Phase One Clinical Trials  \nTechnology in Cancer Research & Treatment Volume 25: 1–11 © The Author(s) 2026 Article reuse guidelines:  \n[sagepub.com/journals-permissions](sagepub.com/journals-permissions)  \n[DOI: 10.1177/15330338261452884](DOI: 10.1177/15330338261452884)  \n[journals.sagepub.com/home/tct](journals.sagepub.com/home/tct)  \nPavan Shet, MD1 , Prerana Ghosh, MD2, Karan Varshney, MD, MBA, MPH3 , and Sameen Sawdagar, MD4  \nAbstract  \nIntroduction: Melanoma is a growing health concern, with global incidence increasing annually. However, treatment for refractory disease is currently limited. Chimeric antigen receptor (CAR) T-cell therapy has shown promising results in haematological malignancies. Despite this, its utility in solid cancers, such as melanoma, is not yet established. We performed a systematic review of phase one trials to help determine and describe foundational understandings ofthe safety and efficacy of CAR T-cell therapy for melanoma. Methods: This systematic review was conducted in accordance with the Cochrane Collaboration Handbook for Systematic Review of Interventions and the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) Statement Guidelines. Databases were searched to identify articles before November 18, 2025, which described the use of CAR T-cell therapy in melanoma patients with published results. Study, patient, and treatment characteristics were summarised and analysed. Results: In total, 2726 articles were screened. Ultimately 5 studies comprising 15 patients with melanoma treated with CART-cell therapy were analysed and discussed. T-cell therapies were all autologous and the targets for the CAR T-cell therapies included GD2, PD-1 and cMET antigens across a wide variety of cell doses. Across pooled data, clinical responses varied, with some patients displaying either a partial or complete clinical response. Treatment related effects were of grade one or two severity, with no serious adverse effects reported, including neurotoxicity side effects, or treatment limited related toxicity/mortality events. Peak expansion typically occurred within day 7 to 28, but persistence was limited across studies. Conclusion: CAR T-cell therapy for melanoma is a novel treatment approach in its infancy. Results are preliminary, and remain largely descriptive, as findings are limited by heterogeneity and small sample sizes. Further investigation through additional phase one trials, and subsequent phase two/three trials, are required for better establishing direct clinical viability.  \nKeywords  \nCAR T-cell therapy, adoptive cellular immunotherapy, melanoma, skin cancer, clinical trials, phase one  \nReceived: 14 December 2025; Revised: 17 April 2026; Accepted: 29 April 2026  \n1Department of Medicine, St.Vincent’s Hospital Melbourne, Fitzroy, VIC, Australia  \n2Department of Medicine, Ballarat Base Hospital, Ballarat Central, VIC, Australia  \n3Department of Medicine, School of Public Health and Preventative Medicine, Monash University, Melbourne, VIC, Australia 4School of Public Health and Preventative Medicine, Second Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China  \nCorresponding author:  \nKaran Varshney, MD, MBA, MPH, Department of Medicine, School of Public Health and Preventative Medicine, Monash University, 553 St Kilda Rd, Melbourne VIC 3004, Australia.  \nEmail: [karan.varshney@monash.edu](karan.varshney@monash.edu)  \nCreative Commons CC BY: This article is distributed under the terms of the Creative Commons Attribution 4.0 License ([https://](https://)[ ](https://)[creativecommons.org/licenses/by/4.0/](creativecommons.org/licenses/by/4.0/)) which permits any use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages ([https://us](https://us).  \n[sagepub.com/","cbCaid6m0OUzxJ2u","https://ap.wps.com/l/cbCaid6m0OUzxJ2u","pdf",1456357,11,"English","# Abstract\n# Introduction\n## Background on melanoma and unmet needs\n## Rationale for CAR T-cell therapy in solid tumors\n# Methods\n## Search strategy and inclusion criteria\n# Results\n## Study selection and patient/treatment characteristics\n## Clinical responses\n## Safety and toxicity findings\n# Conclusion","[{\"question\":\"How were phase one trials selected in the systematic review?\",\"answer\":\"The review followed Cochrane guidance and PRISMA recommendations, searching databases for articles published before November 18, 2025 that reported CAR T-cell therapy in melanoma patients.\"},{\"question\":\"What did the review find about clinical responses in melanoma patients?\",\"answer\":\"Across five included studies (15 patients), pooled responses varied, with some patients achieving either partial or complete clinical responses.\"},{\"question\":\"What safety outcomes were reported for CAR T-cell therapy in these phase one trials?\",\"answer\":\"Treatment-related effects were predominantly grade 1–2, and no serious adverse effects, including neurotoxicity-related events, were reported; limited toxicity and no treatment-related mortality events were described.\"}]","Chimeric Antigen Receptor T-Cell Therapy for the Treatment of Melanoma - A Systematic Review of Phase One Clinical Trials - Preliminaries and Safety/Efficacy Summary | PDF",1790089212,28,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c1c92e73db994ebc174520f6577818ea.webp",983,1310,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7497e6f0103796096e794cb29978326a.webp",982,1309,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/491f5de9288dc9c6ce1d645affd9b881.webp",981,1308,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3481587a7f446cc8cb06a2f16d8d7b64.webp",980,1306]